Matthew Harrison
Stock Analyst at Morgan Stanley
(0.97)
# 1972
Out of 5,328 analysts
894
Total ratings
44.98%
Success rate
1.30%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
GILD Gilead Sciences | Maintains: Overweight | 130 135 | 103.48 | 30.46% | 35 | Apr 25, 2025 | |
SRPT Sarepta Therapeutics | Maintains: Overweight | 196 182 | 63.08 | 188.52% | 35 | Apr 11, 2025 | |
AVIR Atea Pharmaceuticals | Maintains: Equal-Weight | 7 6 | 2.96 | 102.7% | 10 | Apr 11, 2025 | |
BIIB Biogen | Maintains: Equal-Weight | 157 152 | 121.29 | 25.32% | 48 | Apr 9, 2025 | |
MRNA Moderna | Maintains: Equal-Weight | 39 32 | 27.43 | 16.66% | 25 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 82 80 | 34.19 | 133.99% | 11 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 5 | 4.99 | 0.2% | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 5 | 0.5 | 900% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 41 33 | 16.09 | 105.1% | 12 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 450 459 | 500.59 | -8.31% | 34 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 85 90 | 72.8 | 23.63% | 16 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 3 | 1.22 | 145.9% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1235 1184 | 586.15 | 102% | 49 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 4 6 | 1.02 | 488.24% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 8 11 | 13.7 | -19.71% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 38 8 | 1.49 | 436.91% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 515 510 | 643.16 | -20.7% | 24 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 7 | 1.6 | 337.5% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 112 | 62.88 | 78.12% | 20 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 34 34 | 17.57 | 93.51% | 14 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 32 32 | 21 | 52.38% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 42 38 | n/a | n/a | 6 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 14 4 | n/a | n/a | 6 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 321 319 | n/a | n/a | 27 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 21 19 | 1.71 | 1011.11% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 229 229 | n/a | n/a | 23 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Underweight | 60 60 | 4.05 | 1381.48% | 30 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 21 | n/a | n/a | 7 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 46 | 33.87 | 35.81% | 1 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 13 | 2.68 | 385.07% | 4 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.61 | 63.93% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 10 | 18.64 | -46.35% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 27 8 | 4.44 | 80.18% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 44 | 26.84 | 63.93% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 19 10 | n/a | n/a | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 13 | 1.91 | 580.63% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 4 | 0.46 | 769.57% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 0.36 | 733.33% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 203 216 | 103.03 | 109.65% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 5 | 1.46 | 242.47% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 5 | 1.58 | 216.46% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 178 182 | 193.88 | -6.13% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 9 | 4.67 | 92.72% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 40 | 45.66 | -12.4% | 6 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 279 282 | 284.76 | -0.97% | 36 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 220 210 | 252.64 | -16.88% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 736 621 | n/a | n/a | 7 | Sep 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 6 3 | n/a | n/a | 5 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 55 52 | 24.03 | 116.4% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 175 173 | 154.53 | 11.95% | 3 | Apr 6, 2022 |